Register for free to
view the full innovation profile.
IsoL is a prebiotic lozenge to be taken daily - 3 times a day - for long-term management of acid reflux symptoms, with potential to be an alternative to acid reducer medications
About
What is unique about our innovation?
It is a drug-free clinically effective solution for long-term management of acid reflux symptoms, currently covered by acid reducer medication (proton-pump inhibitors or H-2 blockers) which are effective but there are problems such as potential side effects, overuse, users wanting to stop and complex strategies for discontinuation.
How does it work?
IsoL is an isomalt lozenge and should be sucked until complete dissolution. It activates physiological responses of the body: saliva and esophageal peristalsis help clear the acid from esophagus and saliva buffers its pH. Isomalt is a non-digestible carbohydrate with prebiotic properties and could modulate the microbiome towards a more healthy profile. Sucking IsoL 3 times a day, after each meal, in the long-term decreases acid insults to the esophagus and allows recovery. Week-on-week observation of participants of our clinical trial showed an increase in the number of responders to the product.
Simplicity of the product and its ingredients means low COGS, robust supply chain and no need for specialist manufacturing.
Key Benefits
IsoL allows the client to hit a sweet spot in acid reflux symptom management: At the moment millions of consumers are in limbo because managing their diet just does not have the effect they want but at the same they are concerned about the risk of long term medication use. By being able to offer their consumers a more complete spectrum of solutions for long-term management of acid reflux symptoms the client can differentiate themselves from me-too competitor solutions
Applications
Our innovation is applicable to the following markets:
- pregnant women (up-to 80% suffer from acid reflux symptoms;
- bariatric surgery patients (30% of sleeve gastrectomy suffer and cannot take PPIs because they need normal stomach acid to absorb calcium and other supplements);
- PPI users that want to stop (30-40% according to a survey in Germany and UK);
- Acid reflux sufferers in the general population covered by our clinical data (50 to 80% depending on the demographic)